Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst H-A, Récher C, Klimek VM, Cortes JE, Carella A-M, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica [Internet]. 2018Oct.31 [cited 2026Nov.12];103(11):e514-e518. Available from: https://haematologica.org/article/view/8676